Feature

Could home care replace inpatient HSCT?


 

Experience at other centers

The team at Duke is not the first to study HSCT care at home. In fact, researchers in Sweden have been studying posttransplant home care since 1998.

A pilot trial the group published in 2000 suggested that home care was safe and, in some ways, superior to inpatient HSCT (Bone Marrow Transplant. 2000 Nov;26[10]:1057-60). Patients treated at home had a lower rate of bacteremia, fewer days of total parenteral nutrition, fewer erythrocyte transfusions, and fewer days on antibiotics and analgesics. Rates of fever, engraftment time, and acute GVHD were similar between the inpatient and home-care groups.

A study published by the same researchers in 2002 showed that patients who received home care had lower rates of grade 2-4 acute GVHD and transplant-related mortality compared to inpatients (Blood. 2002 Dec 15;100[13]:4317-24). Two-year overall survival was superior with home care as well.

On the other hand, a study the group published in 2013 showed no significant differences in 5-year survival, transplant-related mortality, relapse, or chronic GVHD between inpatients and those who received care at home (Biol Blood Marrow Transplant. 2013. doi: 10.1016/j.bbmt.2012.11.5189).

The phase 2 trials at Duke should provide more insight into patient outcomes, but results probably won’t be available for 2 more years, Dr. Chao said.

In the meantime, other U.S. researchers are studying home care as well. Memorial Sloan Kettering Cancer Center is conducting a pilot study to determine if HSCT care at home is feasible (NCT02671448).

Dr. Chao said home care should be possible for other centers, particularly those that already perform outpatient HSCT.

“Having the outpatient infrastructure to support these patients is a big step,” he said. “And I think we were able to do that mainly because we do most of our transplants in the outpatient setting already. So that jump to the home is a little less compared to a center that does no outpatient transplants.”

He added, “There’s a certain amount of inertia to overcome and a certain amount of apprehension from the caregivers initially because [patients aren’t] sitting in your unit all the time, but I don’t see this as a huge barrier.”

In fact, Dr. Chao said, if results with home care are favorable, it could potentially replace inpatient HSCT for certain patients.

Dr. Chao’s research is supported by Duke University, and he reported having no relevant financial disclosures.

Pages

Recommended Reading

FDA approves first drug for steroid-refractory acute GVHD
MDedge Hematology and Oncology
Survival exceeds 90% in transplant for SCD
MDedge Hematology and Oncology
Recombinant vaccine cut herpes zoster rate in immunocompromised patients
MDedge Hematology and Oncology
Guidelines update donor selection criteria for HSCT
MDedge Hematology and Oncology
Novel conditioning regimen shows benefit for beta-thalassemia major
MDedge Hematology and Oncology
Progressive myeloma after induction? Go straight to transplant
MDedge Hematology and Oncology
Pediatric HSCT recipients still risking sunburn
MDedge Hematology and Oncology
Nonmyeloablative conditioning carries lowers infection risk in patients with AML
MDedge Hematology and Oncology
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
MDedge Hematology and Oncology
VRD pretransplant induction deepens responses in myeloma
MDedge Hematology and Oncology